EWA
CLSD

Exencial Wealth Advisors’s Clearside Biomedical CLSD Stock Holding History

Exencial Wealth Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-938
Closed -$39K – 458
2021
Q4 		$39K Buy
+938
New +$60.8K ﹤0.01% 470
2021
Q3 		– Sell
-938
Closed -$68K – 342
2021
Q2 		$68K Hold
938
– – ﹤0.01% 441
2021
Q1 		$35K Buy
+938
New +$47.1K ﹤0.01% 422

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Exencial Wealth Advisors's CLSD Position: Q1 2022 in Review

Exencial Wealth Advisors sold out of Clearside Biomedical (CLSD) in Q1 2022, closing a stake of 938 shares — an estimated $39K sold.

Exencial Wealth Advisors first reported a position in CLSD in Q1 2021 and held it in 3 quarters. The position peaked at $68K in Q2 2021. 60 funds tracked by Wall St. Rank hold CLSD as of Q1 2022.

  • Exencial Wealth Advisors reported no remaining Clearside Biomedical position as of Q1 2022 after selling out during the quarter.
  • Exencial Wealth Advisors sold 938 Clearside Biomedical shares in Q1 2022, an estimated $39K.
  • Exencial Wealth Advisors first reported a position in Clearside Biomedical in Q1 2021 and held it in 3 quarters.
  • Exencial Wealth Advisors's Clearside Biomedical position peaked at $68K in Q2 2021.
  • 60 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2022.

Based on Exencial Wealth Advisors's 13F filing for Q1 2022, filed 12 May 2022.